Related references
Note: Only part of the references are listed.PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition
Pau Castel et al.
CANCER CELL (2016)
Genomic Classification of Cutaneous Melanoma
Rehan Akbani et al.
CELL (2015)
Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway
A. Hunter Shain et al.
NATURE GENETICS (2015)
PI3′-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF-Mutated Melanoma
Marian M. Deuker et al.
CANCER DISCOVERY (2015)
A Tumor Suppressor Function for the Lipid Phosphatase INPP4B in Melanocytic Neoplasms
Rolando Perez-Lorenzo et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
BRAFV600E Cooperates with PI3K Signaling, Independent of AKT, to Regulate Melanoma Cell Proliferation
Jillian M. Silva et al.
MOLECULAR CANCER RESEARCH (2014)
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Chong Sun et al.
NATURE (2014)
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Matthew Holderfield et al.
NATURE REVIEWS CANCER (2014)
Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation
Pascal Furet et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
RAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms
Ralph Fritsch et al.
CELL (2013)
Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma
Victoria Marsh Durban et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]midazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity
Chudi O. Ndubaku et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo
Christian Posch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349
Zhonghua Pei et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas
Cristina Montero-Conde et al.
CANCER DISCOVERY (2013)
Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines
Ji Eun Kim et al.
BMC CANCER (2012)
Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor
Darrin D. Stuart et al.
CANCER RESEARCH (2012)
A Landscape of Driver Mutations in Melanoma
Eran Hodis et al.
CELL (2012)
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis
Liesbeth C. W. Vredeveld et al.
GENES & DEVELOPMENT (2012)
Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition
Kavitha Gowrishankar et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
Lawrence N. Kwong et al.
NATURE MEDICINE (2012)
PI3K signalling: the path to discovery and understanding
Bart Vanhaesebroeck et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Novel Somatic Mutations to PI3K Pathway Genes in Metastatic Melanoma
Austin Y. Shull et al.
PLOS ONE (2012)
Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)
Kenneth D. Rice et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
Aidan G. Gilmartin et al.
CLINICAL CANCER RESEARCH (2011)
mTOR: from growth signal integration to cancer, diabetes and ageing
Roberto Zoncu et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors
Qing-Bai She et al.
CANCER CELL (2010)
Akt inhibitors in clinical development for the treatment of cancer
Sumanta Kumar Pal et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice
Nathalie Dhomen et al.
CANCER CELL (2009)
AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
Krishna M. Vasudevan et al.
CANCER CELL (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
BrafV600E cooperates with Pten loss to induce metastatic melanoma
David Dankort et al.
NATURE GENETICS (2009)
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Morris E. Feldman et al.
PLOS BIOLOGY (2009)
The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901
Stephen D. Barrett et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity
Nelson Rhodes et al.
CANCER RESEARCH (2008)
Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase
Dirk A. Heerding et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
Adrian J. Folkes et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Oncogene-induced cell senescence - Halting on the road to cancer
W. J. Mooi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Serum and glucocorticoid-regulated protein kinases: Variations on a theme
Maude Tessier et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2006)
PI3-kinase subunits are infrequent somatic targets in melanoma
John A. Curtin et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Mutations of PIK3CA are rare in cutaneous melanoma
K Omholt et al.
MELANOMA RESEARCH (2006)
Genetic alterations in signaling pathways in melanoma
FG Haluska et al.
CLINICAL CANCER RESEARCH (2006)
Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma
Vikas K. Goel et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
BRAFE600-associated senescence-like cell cycle arrest of human naevi
C Michaloglou et al.
NATURE (2005)
The role of B-RAF in melanoma
VC Gray-Schopfer et al.
CANCER AND METASTASIS REVIEWS (2005)
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma
H Tsao et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2004)
Oncogenic mutations of PIK3CA in human cancers
Y Samuels et al.
CELL CYCLE (2004)
BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3
QL Ying et al.
CELL (2003)
High frequency of BRAF mutations in nevi
PM Pollock et al.
NATURE GENETICS (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Share Paper
